Bronchiectasis in COPD patients: More than a comorbidity?

International Journal of COPD

Volumn 12, Issue , 2017, Pages 1401-1411

  Martinez Garcia, Miguel Angel ^a,b   Miravitlles, Marc ^b,c  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

Bronchiectasis; Clinical phenotype; COPD; Exacerbations; Infection; Natural history

Indexed keywords

ANTIBIOTIC AGENT; BRONCHODILATING AGENT; C REACTIVE PROTEIN; CORTICOSTEROID; INTERLEUKIN 6; INTERLEUKIN 8; MACROLIDE; MUCOLYTIC AGENT; PHOSPHODIESTERASE IV INHIBITOR;

AGE; AIRWAY OBSTRUCTION; ARTICLE; BACTERIAL LOAD; BODY MASS; BRONCHIECTASIS; CHRONIC COUGH; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMORBIDITY; DIAGNOSTIC ERROR; DISEASE ASSOCIATION; DISEASE EXACERBATION; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DYSPNEA; EOSINOPHIL; ERYTHROCYTE SEDIMENTATION RATE; EXERCISE; FORCED EXPIRATORY VOLUME; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HOSPITALIZATION; HUMAN; INFLAMMATION; INTERMETHOD COMPARISON; INTERNAL CONSISTENCY; LONGITUDINAL STUDY; MAINTENANCE THERAPY; MICROBIOLOGICAL EXAMINATION; MORTALITY; PHENOTYPE; PREVALENCE; PROGNOSIS; PSEUDOMONAS AERUGINOSA; QUALITY OF LIFE; RISK ASSESSMENT; RISK FACTOR; SMOKING; SPIROMETRY; SPUTUM; TIME; X-RAY COMPUTED TOMOGRAPHY; ADULT; AGED; DIAGNOSTIC IMAGING; FEMALE; LUNG; MALE; MIDDLE AGED; PATHOPHYSIOLOGY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BRONCHIECTASIS; COMORBIDITY; FEMALE; HUMANS; LUNG; MALE; MIDDLE AGED; PHENOTYPE; PREVALENCE; PROGNOSIS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RISK FACTORS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 85019886630     PISSN: 11769106     EISSN: 11782005     Source Type: Journal    
DOI: 10.2147/COPD.S132961     Document Type: Article

References (52)

1. Decramer M, Janssens W, Miravitlles M. Chronic obstructive pulmonary disease. Lancet. 2012; 379 (9823): 1341–1351.
2. Han MK, Agusti A, Calverley PM, et al. Chronic obstructive pulmonary disease phenotypes: the future of COPD. Am J Respir Crit Care Med. 2010; 182 (5): 598–604.
3. Miravitlles M, Calle M, Soler-Cataluña JJ. Clinical phenotypes of COPD: identification, definition and implications for guidelines. Arch Bronconeumol. 2012; 48 (3): 86–98.
4. Bafadhel M, Umar I, Gupta S, et al. The role of CT scanning in multidimensional phenotyping of COPD. Chest. 2011; 140 (3): 634–642.
5. Mair G, Maclay J, Miller JJ, et al. Airway dimensions in COPD: relationship with clinical variables. Respir Med. 2010; 104 (11): 1683–1690.
6. Martinez-Garcia MÁ, Selma MJ, Navarro C, Muñoz-Reina A. Bronchiectasis phenotype in COPD patients. Clin Pulm Med. 2015; 22 (3): 123–127.
7. Lynch DA, Austin JH, Hogg JC, et al. CT-definable subtypes of chronic obstructive pulmonary disease: a statement of the Fleischner Society. Radiology. 2015; 277 (1): 192–205.
8. Cole PJ. Inflammation: a two edged-sword-the model of bronchiectasis. Eur J Respir Dis Suppl. 1986; 147: 6–15.
9. Sethi S, Murphy TF. Infection in the pathogenesis and course of chronic obstructive pulmonary disease. N Engl J Med. 2008; 359 (22): 2355–2365.
10. Miravitlles M, Soriano JB, García-Río F, et al. Prevalence of COPD in Spain: impact of undiagnosed COPD on quality of life and daily life activities. Thorax. 2009; 64 (10): 863–868.
11. Monteagudo M, Rodríguez-Blanco T, Barrecheguren M, Simonet P, Miravitlles M. Prevalence and incidence of bronchiectasis in Catalonia, Spain: A population-based study. Respir Med. 2016; 121: 26–31.
12. Miravitlles M, de la Roza C, Naberan K, et al. Attitudes towards the diagnosis of chronic obstructive pulmonary disease in primary care. Arch Bronconeumol. 2006; 42 (1): 3–8.
13. O’Brien CO, Guest PJ, Hill SL, Stockley RA. Physiological and radiological characterisation of patients diagnosed with chronic obstructive pulmonary disease in primary care. Thorax. 2000; 55 (8): 635–642.
14. Diaz AA, Young TP, Maselli DJ, et al. Quantitative CT measures of bronchiectasis in smokers. Chest. Epub 2016 Nov 24.
15. Gallego M, Pomares X, Espasa M, et al. Pseudomonas aeruginosa isolates in severe chronic obstructive pulmonary disease: characterization and risk factors. BMC Pulm Med. 2014; 14: 103.
16. Martínez-García MÁ, Soler-Cataluña JJ, Donat Sanz Y, et al. Factors associated with bronchiectasis in patients with COPD. Chest. 2011; 140 (5): 1130–1137.
17. Patel IS, Vlahos I, Wilkinson TM, et al. Bronchiectasis, exacerbations indices, and inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2004; 170 (4): 400–407.
18. Roche N, Kouassi B, Rabbat A, Mounedji A, Lorut C, Huchon G. Yield of sputum microbiological examination in patients hospitalized for exacerbations of chronic obstructive pulmonary disease with purulent sputum. Respiration. 2007; 74 (1): 19–25.
19. Garcia-Vidal C, Almagro P, Romaní V, et al. Pseudomonas aeruginosa in patients hospitalised for COPD exacerbations: a prospective study. Eur Respir J. 2009; 34 (5): 1072–1078.
20. Agusti A, Calverley PM, Celli B, et al. Characterisation of COPD heterogeneity in the ECLIPSE cohort. Respir Res. 2010; 11: 122.
21. Arram EO, Elrakhawy MM. Bronchiectasis in COPD patients. Egyptian Journal of Chest Diseases and Tuberculosis. 2012; 61 (4): 307–312.
22. Steward JI, Maselli DJ, Anzueto A, et al. Clinical impact of CT radiological feature of bronchiectasis in the COPDGene cohort. Am J Respir Crit Care Med. 2012; 185: A3656.
23. Martínez-García MA, de la Rosa Carrillo D, Soler-Cataluña JJ, et al. Prognostic value of bronchiectasis in patients with moderate-to-severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2013; 187 (8): 823–831.
24. Tulek B, Kivrak AS, Ozbek S, Kanat F, Suerdem M. Phenotyping of chronic obstructive pulmonary disease using the modified Bhalla scoring system for high-resolution computed tomography. Can Respir J. 2013; 20 (2): 91–96.
25. Gatheral T, Kumar N, Sansom B, et al. COPD-related bronchiectasis; independent impact on disease course and outcomes. COPD. 2014; 11 (6): 605–614.
26. Jairam PM, van der Graaf Y, Lammers JW, Mali WP, de Jong PA; PROVIDI Study group. Incidental findings on chest CT imaging are associated with increased COPD exacerbations and mortality. Thorax. 2015; 70 (8): 725–731.
27. Mao B, Lu HW, Li MH, et al. The existence of bronchiectasis predicts worse prognosis in patients with COPD. Scientific Reports. 2015; 5: 10961.
28. da Silva SM, Paschoal IA, De Capitani EM, Moreira MM, Palhares LC, Pereira MC. COPD phenotypes on computed tomography and its correlation with selected lung function variables in severe patients. Int J Chron Obstruct Pulmon Dis. 2016; 11: 503–513.
29. Kwak HJ, Moon JY, Choi YW, et al. High prevalence of bronchiectasis in adults: analysis of CT findings in a health screening program. Tohoku J Exp Med. 2010; 222 (4): 237–242.
30. Tan WC, Hague CJ, Leipsic J, et al. Findings on thoracic computed tomography scans and respiratory outcomes in persons with and without chronic obstructive pulmonary disease: a population-based cohort study. PLoS One. 2016; 11 (11): e0166745.
31. Ni Y, Shi G, Yu Y, Hao J, Chen T, Song H. Clinical characteristics of patients with chronic obstructive pulmonary disease with comorbid bronchiectasis: a systematic review and meta-analysis. Int J Chron Obstruct Pulmon Dis. 2015; 10: 1465–1475.
32. Du Q, Jin J, Liu X, Sun Y. Bronchiectasis as a comorbidity of chronic obstructive pulmonary disease: a systematic review and meta-analysis. PloS One. 2016; 11 (3): e0150532.
33. Hill AB. The environment and disease: association or causation? Proc R Soc Med.1965; 58 (5): 295–300.
34. Marin A, Monsó E, Garcia-Nuñez M, et al. Variability and effects of bronchial colonisation in patients with moderate COPD. Eur Respir J. 2010; 35 (2): 295–302.
35. Wilkinson TM, Patel IS, Wilks M, Donaldson GC, Wedzicha JA. Airway bacterial load and FEV1 decline in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2003; 167 (8): 1090–1095.
36. Miravitlles M, Marín A, Monsó E, et al. Colour of sputum is a marker for bacterial colonisation in chronic obstructive pulmonary disease. Respir Res. 2010; 11: 58.
37. Peters S. Cystic fibrosis: a review of pathophysiology and current treatment recommendations. S D Med. 2014; 67 (4): 148–151.
38. O’Donnell AE. Bronchiectasis in patients with COPD: a distinct COPD phenotype? Chest. 2013; 140 (5): 1107–1108.
39. Stockley RA. Bronchiectasis with chronic obstructive pulmonary disease: association or a further phenotype? Am J Respir Crit Care Med. 2013; 187 (8): 786–788.
40. Hurst JR, Elborn JS, De Soyza A; BRONCH-UK Consortium. COPD-bronchiectasis overlap syndrome. Eur Respir J. 2015; 45 (2): 310–313.
41. Barker AF, O’Donnell AE, Flume P, et al. Aztreonam for inhalation solution in patients with non-cystic fibrosis bronchiectasis (AIR-BX1 and AIR-BX2): two randomised double-blind, placebo-controlled phase 3 trials. Lancet Respir Med. 2014; 2 (9): 738–749.
42. Matkovic Z, Miravitlles M. Chronic bronchial infection in COPD. Is there an infective phenotype? Respir Med. 2013; 107 (1): 10–22.
43. Martinez-Garcia MA, Maiz L, De la Rosa D. The overlap with bronchiectasis. In: Anzueto A, Heijdra Y, Hurst JR, editors. Controversies in COPD. European Respiratory Society; 2015: 105.
44. Koblizek V, Chlumsky J, Zindr V, et al. Chronic obstructive pulmonary disease: official diagnosis and treatment guidelines of the Czech Pneumological and Phthisiological Society; a novel phenotypic approach to COPD with patient-oriented care. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2013; 157 (2): 189–201.
45. Busch R, Han MK, Bowler RP, et al. Risk factors for COPD exacerbations in inhaled medication users: the COPDGene study bianual longitudinal follow-up prospective cohort. BMC Pulm Med. 2016; 16: 28.
46. Garcha DS, Thurston SJ, Patel AR, et al. Changes in prevalence and load of airway bacteria using quantitative PCR in stable and exacerbated COPD. Thorax. 2012; 67 (12): 1075–1080.
47. Pasteur MC, Bilton D, Hill AT; British Thoracic Society Bronchiectasis non-CF Guideline Group. British Thoracic Society guideline for non-CF bronchiectasis. Thorax. 2010; 65 (Suppl 1): i1–i58.
48. Vogelmeier CF, Criner GJ, Martínez FJ, et al. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary. Arch Bronconeumol. 2017; 53 (3): 128–149.
49. Barrecheguren M, Esquinas C, Miravitlles M. The asthma-chronic obstructive pulmonary disease overlap syndrome (ACOS): opportunities and challenges. Curr Opin Pulm Med. 2015; 21 (1): 74–79.
50. Santos S, Marin A, Serra-Batlles J, et al. Treatment of patients with COPD and recurrent exacerbations: the role of infection and inflammation. Int J Chron Obstruct Pulmon Dis. 2016; 11: 515–525.
51. Shaw JG, Vaughan A, Dent AG, et al. Biomarkers of progression of chronic obstructive pulmonary disease (COPD). J Thorac Dis. 2014; 6 (11): 1532–1547.
52. Tunney MM, Einarsson GG, Wei L, et al. Lung microbiota and bacterial abundance in patients with bronchiectasis when clinically stable and during exacerbation. Am J Respir Crit Care Med. 2013; 187 (10): 1118–1126.